Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).

Sotio Biotech

SOTIO Biotech Group, operating within the PPF Biotech division, researches and develops innovative cancer treatments and applies its scientific immunotherapy knowledge to clinical trials. Teams of
leading experts from all over the world work for SOTIO as part of its extensive international activities.

SOTIO, part of PPF Group since 2012, coordinates the Group’s biotechnology activities. It is building a diversified portfolio of immuno-oncology programmes based on its own research and development, partnerships, licensing agreements, investments, mergers and acquisitions. It has operations in Europe and the US, with principal centres in Prague, Basel, and Boston. SOTIO Group, which has its own scientific and laboratory facilities in Prague, is the largest privately funded research endeavour in the Czech Republic.


SOTIO’s research and development programmes embrace next-generation antibody-drug conjugate (ADC) oncology products, along with personalised cellular immunotherapy on the CAR-T platform and IL–15 superagonist-based products, including immunocytokines.

SOTIO validates the safety and efficacy of its products in comprehensive clinical trials conducted in Europe and the US since 2012. In October 2023, SOTIO signed a licence and option agreement with Dutch company Synaffix to develop next-generation ADCs for the treatment of solid tumours. SOTIO will leverage Synaffix’s ADC technology platform to develop up to three novel ADC programmes for integration into the existing ADC portfolio.

Other PPF Biotech Holdings

Cytune Pharma SAS

Cytune Pharma is a French biotechnology company researching and developing new therapies designed to strengthen the immune response of patients suffering from cancer and infectious diseases. It is member of the SOTIO Biotech group, which develops Interleukin-15-based products based on research of Cytune Pharma.

Autolus Therapeutics

Autolus Therapeutics is a leader in the development of treatments based on CAR-T cells (genetically engineered T cells). The company is dedicated to the clinical development of a wide portfolio of next-generation T-cell therapies targeting both hematological and solid tumors.     

Cellestia Biotech

Cellestia Biotech was founded in 2014 as a spin-off of the Swiss Federal Institute of Technology Lausanne (EPLF). Cellestia’s lead development compound is CB-103, a novel, first-in-class oral pan-NOTCH inhibitor with an innovative mode of action meant for the treatment of patients with NOTCH-driven lymphomas and solid tumors.
Sotio Biotech

"SOTIO exemplifies the world-class standard of Czech science in its mission and results. Our efforts are focused on finding a cure for cancer."

Radek Špíšek

CEO, SOTIO Biotech


SOTIO Biotech a.s.

​​​​​​​Českomoravská 2532/19b
190 00 Prague 9
Czech Republic

Sotio Biotech B.V.

Strawinskylaan 933
1077 XX Amsterdam
The Netherlands

PPF Biotech B.V.

Strawinskylaan 933
1077 XX Amsterdam
The Netherlands